News

Ipsen is developing a new platform of novel neurotoxin derived therapeutics, including TSI, to create new therapeutic opportunities for addressing several medical conditions with unmet requirements. The program

Under the four-year research collaboration, the companies will evaluate the use of CRISPR-Cas9 DNA gene editing technology to address mutations and genes that cause or contribute to cystic

Based on its review conducted to date, Valeant also believes that the company is in compliance with applicable law. In light of the recent allegations made regarding Philidor,

The deal grants Kite an exclusive global license to research, develop and commercialize engineered autologous T cell therapies incorporating two programs from Alpine’s transmembrane immunomodulatory protein (TIP) technology.

The E.coli|360-HCP ELISA allows sponsors and biotech companies to postpone the development of a cost-intensive specific HCP assay until a more informed decision on the success of a

The clinical trial application for the varicella vaccine was officially accepted by the China Food and Drug Administration (CFDA) in January 2013. In preparation to begin human clinical

The systems are synergistic, complementary and work well together. Daylight IQ will now pre-populate select INTERACT forms based on existing nursing documentation. This exchange of data positively impacts

The AAC reviewed safety and efficacy data from the pivotal Phase III combination therapy programme trials, representing the largest clinical trial data set of gout patients treated with

The milestone payment is for pre-clinical progress with a DuoBody product candidate targeting cancer. Janssen has optioned 11 programs out of a total of 20 programs under the